![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CSF3R |
Gene summary for CSF3R |
![]() |
Gene information | Species | Human | Gene symbol | CSF3R | Gene ID | 1441 |
Gene name | colony stimulating factor 3 receptor | |
Gene Alias | CD114 | |
Cytomap | 1p34.3 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q99062 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1441 | CSF3R | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 2.06e-02 | 7.10e-01 | -0.1408 |
1441 | CSF3R | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.11e-25 | 7.39e-01 | -0.0166 |
1441 | CSF3R | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.05e-29 | 8.21e-01 | -0.0132 |
1441 | CSF3R | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.45e-34 | 8.29e-01 | -0.013 |
1441 | CSF3R | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 7.27e-23 | 6.91e-01 | -0.0121 |
1441 | CSF3R | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 5.96e-04 | 6.71e-01 | -0.0961 |
1441 | CSF3R | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.19e-04 | 6.40e-01 | -0.0876 |
1441 | CSF3R | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.11e-04 | 6.88e-01 | -0.0822 |
1441 | CSF3R | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.24e-03 | 5.28e-01 | -0.0809 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00300998 | Lung | IAC | myeloid cell differentiation | 70/2061 | 381/18723 | 1.12e-05 | 3.45e-04 | 70 |
GO:00456378 | Lung | IAC | regulation of myeloid cell differentiation | 36/2061 | 210/18723 | 4.70e-03 | 3.68e-02 | 36 |
GO:19037068 | Lung | IAC | regulation of hemopoiesis | 56/2061 | 367/18723 | 7.23e-03 | 4.94e-02 | 56 |
GO:003009913 | Lung | AIS | myeloid cell differentiation | 63/1849 | 381/18723 | 3.05e-05 | 9.70e-04 | 63 |
GO:004563713 | Lung | AIS | regulation of myeloid cell differentiation | 35/1849 | 210/18723 | 1.43e-03 | 1.74e-02 | 35 |
GO:003009923 | Lung | AAH | myeloid cell differentiation | 29/613 | 381/18723 | 2.44e-05 | 3.42e-03 | 29 |
GO:004563721 | Lung | AAH | regulation of myeloid cell differentiation | 16/613 | 210/18723 | 1.55e-03 | 3.86e-02 | 16 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041514 | Lung | IAC | PI3K-Akt signaling pathway | 60/1053 | 354/8465 | 7.03e-03 | 2.86e-02 | 1.90e-02 | 60 |
hsa0415111 | Lung | IAC | PI3K-Akt signaling pathway | 60/1053 | 354/8465 | 7.03e-03 | 2.86e-02 | 1.90e-02 | 60 |
hsa0415121 | Lung | AIS | PI3K-Akt signaling pathway | 57/961 | 354/8465 | 3.72e-03 | 2.00e-02 | 1.28e-02 | 57 |
hsa0415131 | Lung | AIS | PI3K-Akt signaling pathway | 57/961 | 354/8465 | 3.72e-03 | 2.00e-02 | 1.28e-02 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Breast | Healthy |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | ADJ |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | CC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | Healthy |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Endometrium | EEC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Esophagus | ESCC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | ADJ |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | OSCC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | Precancer |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Prostate | BPH |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Prostate | Healthy |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSF3R | SNV | Missense_Mutation | c.1148N>T | p.Ala383Val | p.A383V | Q99062 | protein_coding | tolerated(0.29) | benign(0.007) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CSF3R | SNV | Missense_Mutation | c.2135N>C | p.Leu712Pro | p.L712P | Q99062 | protein_coding | deleterious(0.02) | probably_damaging(0.974) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CSF3R | SNV | Missense_Mutation | rs372288734 | c.623C>T | p.Ala208Val | p.A208V | Q99062 | protein_coding | tolerated(0.17) | benign(0.001) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSF3R | SNV | Missense_Mutation | novel | c.1145G>T | p.Gly382Val | p.G382V | Q99062 | protein_coding | tolerated(0.16) | possibly_damaging(0.503) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
CSF3R | SNV | Missense_Mutation | novel | c.1838N>C | p.Val613Ala | p.V613A | Q99062 | protein_coding | tolerated(0.29) | benign(0.036) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CSF3R | SNV | Missense_Mutation | c.805N>T | p.Arg269Cys | p.R269C | Q99062 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
CSF3R | SNV | Missense_Mutation | c.1121N>A | p.Ser374Tyr | p.S374Y | Q99062 | protein_coding | deleterious(0) | possibly_damaging(0.833) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CSF3R | SNV | Missense_Mutation | rs373888342 | c.1726G>A | p.Ala576Thr | p.A576T | Q99062 | protein_coding | tolerated(1) | benign(0) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
CSF3R | SNV | Missense_Mutation | novel | c.1622N>T | p.Thr541Ile | p.T541I | Q99062 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CSF3R | SNV | Missense_Mutation | novel | c.2110N>A | p.Pro704Thr | p.P704T | Q99062 | protein_coding | tolerated(0.29) | benign(0.087) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | Filgrastim-SNDZ | FILGRASTIM | ||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | FILGRAMSTIM | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | PLX7486 | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | agonist | CHEMBL1201568 | PEGFILGRASTIM | |
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | MAXY-G34 | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | INS-19 | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | agonist | 178101632 | FILGRASTIM | |
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | PLX-5622 | PLX-5622 | 22294205 | |
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | GLYCOPEG-GCSF | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | FILGRASTIM | FILGRASTIM |
Page: 1 2 3 4 |